Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
Orla Fitzpatrick,1 Jarushka Naidoo1,2 1Department of Oncology, Beaumont Hospital, RCSI University of Health Sciences, Dublin, Ireland; 2Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, 21231, USACorrespondence: Jarushka NaidooBeaumont Hosp...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/01f89d883ac44a82874552e46fc7f16f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|